Last reviewed · How we verify
NCT05586568
Drug-drug Interaction Study of XZP-3621 Tablet
Phase 1 trial testing XZP-3621 tablet and itraconazole oral liquid (for Arm1) in Healthy Subjects in 72 participants. Status unknown.
5 April 2023
Quick facts
| Lead sponsor | Xuanzhu Biopharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 72 |
| Start date | 15 November 2022 |
| Primary completion | 5 April 2023 |
| Estimated completion | 2 August 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- XZP-3621 tablet and itraconazole oral liquid (for Arm1) — full drug profile →
- XZP-3621 tablet and Rifampicin capsules (For Arm 2) — full drug profile →
- XZP-3621 tablet and esomeprazole tablet (For Arm3) — full drug profile →
Conditions studied
- Healthy Subjects — all drugs for Healthy Subjects →
Sponsor
Xuanzhu Biopharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 18 to 65, any sex, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, single center, 2 period, one sequence study to investigate the potential drug drug interaction between itraconazole or rifampin or esomeprazole and XZP-3621 tablet.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05586568
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Subjects
Currently open trials in the same condition.
- NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
- NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
- NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
- NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
- NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting
Other Xuanzhu Biopharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07345689 — A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations · Phase 4 · not yet recruiting
- NCT07330531 — Drug-drug Interaction Study of Rifampin and Anaprazole Sodium · Phase 4 · not yet recruiting
- NCT05478109 — A Clinical Trial of XZP-3287 for Material Balance · Phase 1 · unknown
- NCT05257395 — A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer · Phase 3 · active not recruiting
- NCT05204628 — A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05586568 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuanzhu Biopharmaceutical Co., Ltd.
- Last refreshed: 19 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05586568.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing